Risks

Thin interest coverage and elevated cash burn risk can constrain financing flexibility versus profitable medtech peers, especially if reimbursement or adoption slows.

A very long cash conversion cycle and 101-day receivables collection increase working-capital strain, leaving TNYA more exposed than larger peers with stronger billing leverage.

Low leverage is offset by limited earnings coverage, so any revenue delay can pressure liquidity faster than in better-capitalized neuromodulation peers.

Negative payables dynamics suggest supplier financing is not a durable buffer, reducing resilience versus peers that can stretch working capital more effectively.

Opportunities

A current ratio above 4.5 provides near-term liquidity headroom, giving TNYA more runway than highly levered peers to support commercialization and reimbursement execution.

Low debt-to-equity and modest net debt reduce balance-sheet drag, which can help TNYA preserve strategic flexibility versus more indebted device peers.

If adoption of its therapy platform continues, the company can convert operating leverage from a small revenue base faster than larger, slower-growing peers.

Working-capital normalization would materially improve cash generation, and that upside is more pronounced here than at peers with already efficient collections.

Overall Score

TNYA’s strong liquidity and low leverage support near-term positioning, but weak coverage and stretched working capital keep peer-relative execution and financing risk material.